|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 242.10 EUR | -1.98% |
|
-4.53% | +12.50% |
| 12-12 | Sartorius Kept at Sell as mwb Research Highlights Structural Pressure | MT |
| 12-10 | MedTech Stocks Diverge Following Exane Report: 'A Split 2026' | DP |
Business description: Sartorius AG
Number of employees: 13,878
Sales by Activity: Sartorius AG
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
Bioprocess Solutions | 1.78B | 2.73B | 3.33B | 2.68B | 2.69B |
Lab Products & Services | 553M | 722M | 848M | 718M | 690M |
Geographical breakdown of sales: Sartorius AG
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
USA | 755M | 1.06B | 1.44B | 1.16B | 1.11B |
Other EMEA | 629M | 967M | 1.06B | 883M | 938M |
Other Asia Pacific | 234M | 356M | 412M | 352M | 380M |
Germany | 210M | 318M | 350M | 304M | 291M |
China | 224M | 379M | 471M | 276M | 242M |
South Korea | 130M | 162M | 198M | 171M | 170M |
France | 96.08M | 126M | 145M | 129M | 160M |
Other Americas | 56.95M | 79.51M | 102M | 119M | 92.8M |
Executive Committee: Sartorius AG
| Manager | Title | Age | Since |
|---|---|---|---|
Michael Grosse
CEO | Chief Executive Officer | 58 | 2025-06-29 |
Florian Funck
DFI | Director of Finance/CFO | 54 | 2024-03-31 |
Volker Niebel
COO | Chief Operating Officer | 69 | 2000-12-31 |
| Chief Tech/Sci/R&D Officer | 61 | 1994-12-31 | |
Petra Kirchhoff
IRC | Investor Relations Contact | 56 | 2010-12-31 |
Composition of the Board of Directors: Sartorius AG
| Director | Title | Age | Since |
|---|---|---|---|
Annette Becker
BRD | Director/Board Member | 61 | 2002-08-31 |
Lothar Kappich
CHM | Chairman | 68 | 2017-07-08 |
Petra Kirchhoff
BRD | Director/Board Member | 56 | 2010-09-30 |
| Director/Board Member | 77 | 2011-11-28 | |
Manfred Zaffke
BRD | Director/Board Member | 68 | 2014-02-28 |
Daniela Favoccia
BRD | Director/Board Member | 61 | 2017-04-05 |
| Director/Board Member | 59 | 2017-04-05 | |
David Ebsworth
BRD | Director/Board Member | 70 | 2019-12-31 |
Dietmar Müller
BRD | Director/Board Member | 49 | 2020-05-15 |
| Director/Board Member | 59 | 2021-02-28 |
Holdings: Sartorius AG
| Name | Equities | % | Valuation |
|---|---|---|---|
SARTORIUS STEDIM BIOTECH 73.6% | 71,635,178 | 73.6% | 17,234,135,826 $ |
SARTORIUS AG 7.03% | 2,632,732 | 7.03% | 767,520,781 $ |
BICO GROUP AB 6.06% | 4,185,658 | 6.06% | 9,399,355 $ |
Company details: Sartorius AG
Group companies: Sartorius AG
| Name | Category and Sector |
|---|---|
Medical Specialties
| |
Medical Specialties
| |
Sartorius Stedim Biotech GmbH
 Sartorius Stedim Biotech GmbH Medical SpecialtiesHealth Technology Produces and sells laboratory equipment used for the development, quality assurance and production processes of the biopharmaceutical industry |
Medical Specialties
|
Sartorius Stédim FMT SAS
 Sartorius Stédim FMT SAS Manufactures plastic packaging products | |
Sartorius Stédim FMT SAS
Sartorius Stédim FMT SAS Manufactures plastic packaging products |
Medical Diagnostic & Testing Equipment
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -1.98% | -4.53% | +6.23% | -34.57% | 17.45B | |
| -3.23% | -4.47% | +83.66% | +246.46% | 2.52B | |
| -2.90% | +3.75% | -30.35% | -64.91% | 1.96B | |
| -1.11% | -2.39% | -1.13% | -9.76% | 1.11B | |
| -1.13% | -1.26% | +3.02% | -23.83% | 899M | |
| +0.65% | -2.89% | -3.20% | -46.54% | 879M | |
| +0.89% | +2.71% | -15.87% | -43.58% | 710M | |
| -2.49% | -11.02% | +274.23% | - | 495M | |
| -0.43% | +1.12% | -24.16% | -41.68% | 488M | |
| -0.39% | -1.92% | -32.36% | -39.45% | 393M | |
| Average | -1.21% | -1.54% | +26.01% | -6.43% | 2.69B | |
| Weighted average by Cap. | -1.90% | -3.62% | +13.34% | -9.43% |
Sector
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- SRT3 Stock
- Company Sartorius AG
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition